Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

Neurology. 2008 Mar 25;70(13 Pt 2):1150-1. doi: 10.1212/01.wnl.0000265393.03231.e5. Epub 2007 Sep 13.
No abstract available

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Brain / drug effects*
  • Brain / pathology*
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / pathology*
  • Multiple Sclerosis / physiopathology
  • Natalizumab
  • Nerve Fibers, Myelinated / drug effects
  • Nerve Fibers, Myelinated / immunology
  • Nerve Fibers, Myelinated / pathology
  • Placebos
  • Recurrence
  • Substance Withdrawal Syndrome / pathology*
  • Substance Withdrawal Syndrome / physiopathology
  • Time

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Natalizumab
  • Placebos